Don’t let the public pronouncements of pain for pharma from healthcare reform confuse you. Big pharma has had the expansion of health insurance and finding deep pockets to cover the uninsured as its major goal for years. Pharma execs and policy people are trying to sound worried; it is hard.
Cole Werble
Sometimes, it's tough for pharma execs to rein in their exuberance about the big new market awaiting the industry on...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Patient access to mental health drugs also will be challenged by the policies in the new budget reconciliation legislation.
States also agreed to fund patient travel to specialized treatment centers as part of their participation in the Medicaid demo of CMS-negotiated outcomes-based contracts for Vertex/CRISPR's Casgevy and bluebird bio's Lyfgenia.
The issue is attracting more attention as the 2028 deadline for implementing Medicare negotiated prices for Part B drugs approaches.
PTC Therapeutics is continuing to supply its Duchenne muscular dystrophy treatment, Translarna, in some European markets, despite EU revocation of the drug’s conditional marketing authorization earlier this year.
As the European Commission prepares a formal evaluation of the SPC manufacturing waiver, the generics and biosimilars industry is getting ready to provide detailed feedback on what works – and what doesn’t. At Medicines for Europe’s legal affairs conference, delegates heard the latest updates.
The AI observatory, created by the European medicines regulatory network to track the evolving use of artificial intelligence in medicines development and regulation, has issued its first annual report.
In defending his decision to overrule agency staff on three recent COVID-19 vaccine applications, the CBER director questioned the original timing of Pfizer’s COVID-19 vaccine authorization, reviving a long-held, but unproven grievance of President Trump.
